Skip to main content
NanoVibronix, Inc. logo

NanoVibronix, Inc. — Investor Relations & Filings

Ticker · NAOV ISIN · US63008J7028 LEI · 5493008114LTFZQ2I595 US Manufacturing
Open in API
Filings indexed 512 across all filing types
Latest filing 2023-09-01 Capital/Financing Update
Country US United States of America
Listing US NAOV

About NanoVibronix, Inc.

https://nanovibronix.com/

NanoVibronix, Inc. is a medical technology company that develops non-invasive and minimally invasive biological response-activating devices. The company's core technology is based on a proprietary, patented low-intensity surface acoustic wave (SAW) ultrasound. Its main products include PainShield®, a portable device for pain therapy and the treatment of nerve and soft tissue damage, and UroShield®, an ultrasound device designed to prevent bacterial biofilm on urinary catheters. These prescription-based products offer therapeutic alternatives to medication for pain management, wound healing, and biofilm prevention, targeting both clinical and home care settings.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details a private placement financing transaction, including the issuance of common stock, pre-funded warrants, and other warrants, as well as the engagement of a placement agent and related agreements. There are no financial statements or comprehensive financial data presented, only disclosures about the capital raising event and related agreements. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is 9771 characters, which is substantive and not a mere announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2023-09-01 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes a press release about positive test results for a product and references Item 7.01 (Regulation FD Disclosure). The document does not contain financial statements or detailed financial data but rather furnishes a press release as an exhibit. The length is 4131 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. According to the rules, such filings that provide announcements or press releases without substantive financial data or full reports should be classified as Regulatory Filings (RNS).
2023-08-30 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 29, 2023, by NanoVibronix, Inc. It includes a press release about the company's response to a CMS payment determination for a product. The document explicitly states it is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and includes a press release as Exhibit 99.1. There are no financial statements or detailed financial data included, only a press release announcement. The document length is 4156 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report filing with a press release and does not contain substantive financial data or detailed report content. It is not an earnings release, annual report, or other detailed financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-29 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes a Regulation FD Disclosure about a press release regarding the company's application for inclusion of its product in a drug tariff. The document is short (4142 characters) and primarily serves to announce this event and furnish the press release as an exhibit. There are no financial statements or detailed financial data included. This type of filing is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-08-28 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (an amendment to a distribution agreement) and includes a press release about this event. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a material contract amendment and related press release, typical of a Regulatory Filing (RNS). The document length is 4399 characters, which is relatively short and consistent with a Form 8-K announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-23 English
10-Q Filing
Interim / Quarterly Report Q2 2023
2023-08-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.